SAB Biotherapeutics, Inc. (SABSW) Stock Overview
Explore SAB Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
SAB Biotherapeutics, Inc. (SABSW)
Key Financials
Key Financials
Market Cap
95.6K
P/E Ratio
-537.70
EPS (TTM)
$0.29
ROE
-0.00%
SABSW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of SAB Biotherapeutics, Inc. (SABSW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 44.68, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.14.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -537.70 and a market capitalization of 95.6K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.